SG11202007319SA - Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers - Google Patents
Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkersInfo
- Publication number
- SG11202007319SA SG11202007319SA SG11202007319SA SG11202007319SA SG11202007319SA SG 11202007319S A SG11202007319S A SG 11202007319SA SG 11202007319S A SG11202007319S A SG 11202007319SA SG 11202007319S A SG11202007319S A SG 11202007319SA SG 11202007319S A SG11202007319S A SG 11202007319SA
- Authority
- SG
- Singapore
- Prior art keywords
- preeclampsia
- prevention
- methods
- early prediction
- associated biomarkers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Immunology (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Evolutionary Computation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862624626P | 2018-01-31 | 2018-01-31 | |
US201862641135P | 2018-03-09 | 2018-03-09 | |
PCT/US2019/016188 WO2019152741A1 (en) | 2018-01-31 | 2019-01-31 | Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007319SA true SG11202007319SA (en) | 2020-08-28 |
Family
ID=67479860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007319SA SG11202007319SA (en) | 2018-01-31 | 2019-01-31 | Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210050112A1 (en) |
EP (1) | EP3746087A4 (en) |
JP (1) | JP2021512315A (en) |
KR (1) | KR20200140796A (en) |
CN (1) | CN111918658A (en) |
SG (1) | SG11202007319SA (en) |
WO (1) | WO2019152741A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022015666A1 (en) * | 2020-07-13 | 2022-01-20 | Nx Prenatal Inc. | Methods of assessing risk of and treating preeclampsia and subtypes thereof |
WO2023087004A2 (en) * | 2021-11-11 | 2023-05-19 | Nx Prenatal Inc. | Methods of preparing and analyzing samples for biomarkers associated with placenta accreta |
WO2023247308A1 (en) * | 2022-06-21 | 2023-12-28 | Neopredix Ag | Preeclampsia evolution prediction, method and system |
CN117747110A (en) * | 2023-12-26 | 2024-03-22 | 南京鼓楼医院 | Preeclampsia risk prediction method and preeclampsia risk prediction system based on maternal factors and early pregnancy biomarkers |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009097584A1 (en) * | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
US20140186332A1 (en) * | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
SG11201506891YA (en) * | 2013-03-12 | 2015-09-29 | Agency Science Tech & Res | Pre-eclampsia biomarkers |
WO2015002845A1 (en) * | 2013-07-01 | 2015-01-08 | Anderson Cindy | Biomarker for preeclampsia |
EP3189336B1 (en) * | 2014-09-02 | 2018-11-07 | Wallac OY | Method for determining risk of pre-eclampsia |
AU2016279002B2 (en) * | 2015-06-19 | 2022-06-30 | Sera Prognostics, Inc. | Biomarker pairs for predicting preterm birth |
GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
EP3384076A4 (en) * | 2015-12-04 | 2019-09-25 | Nx Prenatal Inc. | Use of circulating microparticles to stratify risk of spontaneous preterm birth |
-
2019
- 2019-01-31 KR KR1020207024673A patent/KR20200140796A/en not_active Application Discontinuation
- 2019-01-31 CN CN201980022348.1A patent/CN111918658A/en active Pending
- 2019-01-31 JP JP2020541680A patent/JP2021512315A/en active Pending
- 2019-01-31 SG SG11202007319SA patent/SG11202007319SA/en unknown
- 2019-01-31 EP EP19747991.8A patent/EP3746087A4/en active Pending
- 2019-01-31 WO PCT/US2019/016188 patent/WO2019152741A1/en unknown
-
2020
- 2020-07-31 US US16/945,642 patent/US20210050112A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021512315A (en) | 2021-05-13 |
US20210050112A1 (en) | 2021-02-18 |
EP3746087A1 (en) | 2020-12-09 |
KR20200140796A (en) | 2020-12-16 |
EP3746087A4 (en) | 2022-02-09 |
WO2019152741A1 (en) | 2019-08-08 |
CN111918658A (en) | 2020-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274802A (en) | Hybrid method of assessing and predicting athletic performance | |
SG11202007319SA (en) | Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers | |
SG11202103661XA (en) | Inter prediction method and apparatus | |
EP3543880A4 (en) | Stroke diagnosis and prognosis prediction method and system | |
SG11202100063YA (en) | Inter prediction method and apparatus | |
GB201810897D0 (en) | Phenotype prediction | |
GB2549761B (en) | An automatic door installation and method of determining the presence of an obstacle | |
HK1251877A1 (en) | Biomarkers and methods of prediction | |
HK1257108A1 (en) | Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers | |
IL267885B (en) | Methods and systems for computer-based determining of presence of objects | |
GB201701203D0 (en) | Stepped spiral chute assembly having friction reduction panels and method of forming same | |
IL290879A (en) | Method of isolating circulating nucleosomes | |
GB201810190D0 (en) | Prognostic and treatment response predictive method | |
SG11202003130TA (en) | Prognostic and treatment response predictive method | |
GB2570542B (en) | Steel profile and method of processing steel | |
ZA202100106B (en) | Methods of treating and/or preventing actinic keratosis | |
GB201719639D0 (en) | Setection of biomarkers | |
EP3669188C0 (en) | Method and system for prediction of concrete maturity | |
HK1248810A1 (en) | Biomarkers for diagnosis and prognosis of corneal ectatic disorders | |
EP3655433A4 (en) | Methods and uses of inflammatory bowel disease biomarkers | |
GB201619808D0 (en) | Biomarkers for the prognosis and diagnosis of cancer | |
GB201910133D0 (en) | Method of prognosing and diagnosing preeclampsia | |
GB201907550D0 (en) | Detection of biomarkers | |
EP3889569A4 (en) | Ambient-hydrogen-level assessment method and white-structure-damage-likelihood prediction method | |
EP3679160A4 (en) | Method of using biomarkers and clinical variables for predicting chemotherapy benefit |